Trial
NCT03199040
Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Washington University School of Medicine
Collaborators
MedImmune LLC; National Cancer Institute (NCI); National Institutes of Health (NIH)
Condition
Triple Negative Breast Cancer
Intervention
Durvalumab
Why stopped
Drugs/equipment unavailable and insufficient funding
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-05-28